Tirzepatide produced greater average weight loss in a direct 72-week obesity trial, while semaglutide has a cardiovascular risk-reduction indication for certain adults
Moreover, it proved more effective and to have fewer adverse gastrointestinal side effects than existing drugs that just targeted GLP-1 (Finan, Ma, Ottaway)
"It was like something opened up in my mind and said: 'Eat everything, go on, you deserve it because you haven't eaten anything for so long'." Tanya, a sales manager for a large fitness company, first started taking Wegovy to prove a point
In the MASLD substudy, two retatrutide-treated participants, or 2.5%, experienced a total of three serious adverse events [6]
Products and their starting costs include: Wegovy Pill: $149/month Foundayo Pill: $149/month Wegovy Pen: $199/month Ozempic: $199/month Zepbound Vial: $299/month Zepound KwikPen: $299/month Mounjaro: $1,899/month Zepound: $1,899/month Note that because the FDA has announced it is taking action on non-FDA approved GLP-1s, you may see fewer compounded options
The abdomen